HBRM Herborium Group, Inc.

[stevo51]

HBRM .0248 ,,,,Herborium Group, Inc. Focuses on a Lucrative Botanical Therapeutics Market

SADDLE BROOK, NJ, May 28, 2010 (MARKETWIRE via COMTEX) -- Herborium Group, Inc. (PINKSHEETS: HBRM) (www.herborium.com), a botanical therapeutics(R) company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine.
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.

Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- www.acnease.com), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.

"With the conversion of such factors as health economics, directing consumers to spend money on prevention and on non ethical products (lower insurance coverage) and to pharmaceutical companies being forced to remove drugs from the market for safety reasons (La Roche and Accutane for acne or Vioxx for pain), Herborium is ideally positioned to take advantage of those emerging market opportunities," said Dr. Agnes P. Olszewski, President of Herborium Group. "During last four months we have focused our activities on preparing to penetrate new markets with our existing products including targeting of foreign markets. We have signed or are in final stage of negotiating new distribution agreements in the USA and abroad that will greatly increase our customer base. We expect that our bottom line will significantly benefit from those initiatives in 2010 and 2011," continues Dr. Olszewski.

"We are also planning to introduce new and complementary products. We are especially excited about expected product line extension in the field of dermatology with a product targeting acne," adds Dr. Olszewski

"While securing additional resources we plan to address needs of consumers and health providers that look for highly efficient, proven safe and effective all natural alternatives in treatment and prevention of number of health problems and concerns," concludes Dr. Olszewski

About Herborium Group, Inc. Herborium Group, Inc., a botanical therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the forms 10-Q.



Company Contact:
Dr. Agnes P. Olszewski
President & CEO
Tel: (201) 647.3757


SOURCE: Herborium Group, Inc.

[stevo51]

http://smallcapsociety.com/hbrm.php

[stevo51]

http://www.microcapreports.com/herborium

[stevo51]

Based on these public estimates the stock price of HBRM could soar up 790% in the near term and more than 2,327% this year.

With 68% margins and 200 million shares outstanding at 19X EPS…

Target Share Price = $.67 for 2010 and $1.34 for 2011

Herborium, Inc.’s (HBRM) business plan is to raise expansion capital for new healthcare market opportunities and reach $10 million in sales for 2010 with a gross profit margin of 68%. Then in 2011 the company’s projections are for $20 million in sales with a similar high gross profit margin.

[stevo51]

(OTC: HBRM) Launches in the Trillion Dollar Global Alternative Medicine Sector

Marketwire "Press Releases "
NEW YORK, NY -- (MARKET WIRE) -- 06/01/10 --
Herborium Group, Inc. (PINKSHEETS: HBRM) announced that they are focusing their efforts on developing aggressive routes to tapping into the over the counter alternative medicine and complementary medicine market.




Plants have been used as a source of medicine throughout history and continue to serve as the basis for many pharmaceuticals used today. Although the modern pharmaceutical industry was born from botanical medicine, synthetic approaches to drug discovery have become standard. However, this modern approach has led to a decline in new drug development in recent years and a growing market for botanical therapeutics that are currently available as dietary supplements, drugs, or botanical drugs. Herborium initially aims to take on some of the most wide reaching afflictions that affect Americans, acne and benign prostate hyperplasia (BPH). These two focuses open up a 77 billion dollar market.




For more information, please visit www.smallcapsociety.com/hbrm.php

[stevo51]

Good morning subscriber's. We at Micro Cap Reports hope you had a safe and relaxing holiday weekend. This morning we want to alert you again to Herborium Group, Inc. HBRM.PK.

The company had a great week last week as they released news to the investor community that has stimulated investors' interest into this growing botanical therapeutics company. They are quietly staking their claim in this burgeoning 250 billion dollar sector.

We want to refresh your memory as it relates to HBRM.PK

http://stockcharts.com/h-sc/ui?s=hbrm

http://www.herborium.com/indexalt.html

http://finance.yahoo.com/news/Herbor....html?x=0&.v=1

Herborium Group, Inc., is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.

The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 Billion in the USA and UK alone.


Their Mission
Herborium strives to become the Leader in developing and marketing novel, safe and effective, proprietary botanical therapeutics® (botanical based medicines), and innovative support content which target selected, unmet medical needs for disease treatment, management, and prevention.

Why Herborium Group?

Synthetic drugs continue to have problems with the FDA and produce unwanted side-effects...leaving major markets wide open for Herborium to penetrate.

Herborium's natural product lines demonstrate effectiveness without these traditional chemical pharmaceutical ingredients.

Herborium's Founder and CEO is Dr. Agnes P. Olszewski Ph.D, MBA. She has gathered an executive team and advisory board with past experience at: Pfizer Inc., Penn Pharmaceutical and Johns Hopkins School of Medicine

SCIENCE + NATURE = HERBORIUM, Inc. (HBRM)

The FDA made big policy changes in 2004...
This has allowed Herborium to conduct clinical studies to prove that the company's products are safe and effective.

Directives in the European Union now require new herbal medications to be clinically tested before being released to the public.

Proven clinical efficacy is a new barrier to the natural supplement market that gives Herborium favored product positioning.

In order to gain an edge on the competition:
Herborium's management has focused on staying on top of regulatory requirements throughout the world - in the United States, European Union and United Kingdom alike.

http://www.fda.gov/ICECI/ComplianceM...al/default.htm


Company Milestones

Technology Ownership (IP)

Exclusive distribution rights

Exclusive licenses

Focused, strategic partnerships

Brand recognition ( AcnEase vs. Accutane)

Revenue generation

Successful first round of financing.



Micro Cap Reports

If you like what you see here, please visit us at our website,

http://www.microcapreports.com

June 1st, 2010

Always do your own due diligence and know your risk tolerance for profit and loss.

[stevo51]

Good morning subscribers. This morning we are still buzzing over Herborium Group Inc., HBRM.PK. The company is gaining traction in the market place with investors. We had one question. Do their products work? Well, we did some digging to find out what the reviews were saying. What we found out was that they do work. AcnEase is their flagship product so we are bringing you reviews of it this morning. Read on and make up your own mind to the efficacy of the product.

The company is stepping into the acne arena armed with a product that effectively treats the diseased area without the use of a topical treatment. No creams or ointments to apply multiple times daily.

The market for OTC acne treatments alone was projected to pass the 550 million dollar mark by the year 2008. This dollar amount reperesents nearly 17% of the OTC medicated skin care market.

http://www.majormarketprofiles.com/r...d=26585&s=snap


As a population, the USA has the largest percentage of overweight teens and young adults, those most likely to contract acne through poor diet alone.

As you can see, the market demand for AcnEase, coupled with the fact it really works, makes for an easy entry for Herborium Group to step onto the center stage as a leading provider for over the counter skin care treatment.

http://www.aragonproducts.com/thepro...fm?master=7566

The science behind AcnEase. AcnEase is a proprietary herbal acne treatment that was developed based on principles of Traditional Chinese Medicine and modern herbaceutical and pharmacological science. This all natural product is formulated with a Patented and Trade Secret protected blend of the highest quality herbal extracts.

The ability of AcnEase to serve as a natural acne treatment and to provide a natural acne cure is assured by extensive testing and strictly controlled manufacturing conditions. The ratio of the ingredients, the selection of herbs and the method of extraction are key factors in assuring the efficacy of AcnEase as a premium natural acne treatment.

Benefits: This unique acne treatment works in several ways: AcnEase prevents the forming of new pimples, whiteheads and blackheads and significantly improves symptoms associated with Adult Acne, Cystic Acne, Teen Acne and Body Acne.

AcnEase also reduces facial flushing and the incidence of blepheritis (itchy gritty eyes) and gastric reflux (heartburn), symptoms often associated with Rosacea.

http://www.onlineacneinfo.org/acne-p...cnease-review/

Get Rid of Acne from the Inside Out with AcnEase

While there are many products out there that are supposed to treat the acne problem, unfortunately not all of them are effective. In fact, some acne treatments actually end up doing more harm than good to your skin. For this reason, more and more people are beginning to turn to some of the natural acne treatments that are available. One excellent natural treatment out there that has proven to be very effective at treating acne is the product AcnEase. There are a variety of reasons that this products is definitely one of the best.

The Acne Problem is Properly Addressed

One of the reasons that AcnEase is such a great acne product is because it actually properly addresses the acne problem. There are many different products out there that only deal with treating the symptoms of acne; however, AcnEase actually works to get to the bottom of the problem. Instead of treating acne topically, this product treats the acne from the inside out and actually helps to balance out the body on the inside so that acne is no longer a problem that has to be dealt with. Although it can take a couple weeks to start showing results, the results are usually long lasting.


AcnEase Review

Acne problems are worse. They do not only damage your skin, but spoils your life as well. Several products have been sold in the market to treat this problem; but nothing came as close as AcnEase in treating acne infection. Find out more about this product by reading the review below.

http://hubpages.com/hub/acnease-review





Micro Cap Reports

http://www.microcapreports.com

June 2nd, 2010

[stevo51]

Herborium Group Commences AcnEase(R) Retail Sales
AcnEase(R) Now Available in New York Dermatology Clinics

Press Release Source: Herborium Group, Inc. On Wednesday June 2, 2010, 4:00 pm
SADDLE BROOK, NJ--(Marketwire - 06/02/10) - Herborium Group, Inc., (Pinksheets:HBRM - News), a Botanical Therapeutics(TM) company, today announced it has now successfully secured direct consumer points-of-sale for its flagship product, AcnEase®, with a recognized group of New York dermatological clinics.

"Acceptance of AcnEase by board certified dermatologist to be sold in the clinics is a major third-party validation of the therapeutic value of our product, and is an important cornerstone in building the AcnEase® brand," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer.

AcnEase® is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase.

In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating (http://www.acnease.com/).

Dr. Olszewski continued, "Expanding beyond e-commerce (internet sales) to direct consumer points-of-sale is an important milestone in our overall plan to increase AcnEase sales and brand recognition and grow market share within the US 3.5 billion over the counter medicated skin care market

"With the current surge in sales of over-the-counter nutritional and health supplements, combined with Hoffmann-La Roche Inc.'s announcement to discontinue marketing of its leading treatment for severe acne, Accutane® (isotretinoin), and Herborium's AcnEase product's demonstrated and documented over five year history of safe and effective acne treatment, I firmly believe we have the right product, at the right time, for over 50 million acne sufferers in the USA.

"Having successfully launched our direct-to-consumer sales strategy with AcnEase in the US market , we intend to replicate this strategy to the extent justified "by market conditions" in International markets, while we prepare our next product sales initiative to access the US cosmeceutical market expected to potentially reach over $16 billion by 2010.

"Herborium is committed to continue developing a global brand with a strong international distribution network, and the acceptance of AcnEase by the dermatological community is a key development in both product branding and sales growth strategies," Dr. Olszewski concluded.


About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.

Adino Energy Corporation urges investors to review the risks and uncertainties contained within its filings with the Securities and Exchange Commission.



Company Contact:

Dr. Agnes P. Olszewski, President & CEO
201-647-3757

[stevo51]

Investor Clueso Subsribers,

We LOVED the AH news on HBRM yesterday! HBRM: Successfully secured direct consumer points-of-sale for its flagship product, AcnEase®.

The stock is trading very nicely with steady accumulation. With a relatively small float for the price, we believe HBRM has tremendous potential. Volume is always key in trading any stock and HBRM is definately attracting significant volume these days.

HBRM Share Structure:
May 7th, 2010
O/S 147,470,708
FLOAT 41,960.487
RESTRICTED 105,510,221

Herborium Group Commences AcnEase(R) Retail Sales
AcnEase(R) Now Available in New York Dermatology Clinics
Jun 2, 2010 3:00:00 PM

Herborium Group, Inc., (HBRM), a Botanical Therapeutics? company, today announced it has now successfully secured direct consumer points-of-sale for its flagship product, AcnEase®, with a recognized group of New York dermatological clinics.

"Acceptance of AcnEase by board certified dermatologist to be sold in the clinics is a major third-party validation of the therapeutic value of our product, and is an important cornerstone in building the AcnEase® brand," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer.

AcnEase® is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase. In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating (www.acnease.com).

Dr. Olszewski continued, "Expanding beyond e-commerce (internet sales) to direct consumer points-of-sale is an important milestone in our overall plan to increase AcnEase sales and brand recognition and grow market share within the US 3.5 billion over the counter medicated skin care market

"With the current surge in sales of over-the-counter nutritional and health supplements, combined with Hoffmann-La Roche Inc.'s announcement to discontinue marketing of its leading treatment for severe acne, Accutane® (isotretinoin), and Herborium's AcnEase product's demonstrated and documented over five year history of safe and effective acne treatment, I firmly believe we have the right product, at the right time, for over 50 million acne sufferers in the USA.

"Having successfully launched our direct-to-consumer sales strategy with AcnEase in the US market , we intend to replicate this strategy to the extent justified "by market conditions" in International markets, while we prepare our next product sales initiative to access the US cosmeceutical market expected to potentially reach over $16 billion by 2010.

"Herborium is committed to continue developing a global brand with a strong international distribution network, and the acceptance of AcnEase by the dermatological community is a key development in both product branding and sales growth strategies," Dr. Olszewski concluded.

About Herborium Group, Inc.

Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases,
Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events.

Company Contact:
Dr. Agnes P. Olszewski
President & CEO
(201) 647-3757 (201) 647-3757

[stevo51]

Good morning investors and traders. The last week the staff at Micro Cap Reports has focused on The Herborium Group Inc. We have had the company on our radar and in our portfolio for several months now.
This morning we are bringing to you the leadership team of Herborium Group. The management of the company has decades of experience working with The People's Republic of China, Yale University, Seton Hall University and Unigene Inc., to name a few.


They have the capability and expertise to bring a product from the research and develpoment stages through clinical trials to the ultimate in the USA, an FDA approval.

The management team is comprised of the following four individuals who are listed below. Follow the links provided for your due diligence to read how they have arrived here today. This is no overnight success story. It has been years in the making.

Herborium Group Inc. Management Profiles:


Agnes P. Olszewski, Ph.D. MBA; Founder, President, CEO
Dr. Olszewski, co-founder of Herborium, has over 20 years experience in business strategy, strategic marketing management and international business. She is an Associate Professor at Seton Hall University in the marketing department with a focus in international business. She holds an MA and Ph.D. degrees from Warsaw University, Poland, and an MBA from Fordham University, New York City. Dr. Olszewski has been a consultant and a team leader on strategic management and competitive marketing strategies for leading American corporations as well as foreign companies and institutions. In her capacity as an international consultant she had lead multicultural negotiations and managed diverse teams of professionals in the USA, Asia and Europe. She has also been responsible for developing and implementing business and marketing strategies in the US and foreign markets.


Dr. Olszewski's client list includes: AT&T, Johnson & Johnson, Nynex Communications, Unigene Laboratories Inc., Polish Airlines "LOT", Ministry Of Foreign Trade and Economic Collaboration of PRC, UNDP, Graphica Inc. amongst others. She has also been a Small Business Advisor and the Member of the Global Round Table for the State of New Jersey. Dr. Olszewski has been conducting business in China for nearly 20 years.


After the collapse of communism in Central Europe, Dr. Olszewski formed A&T Global Marketing Inc., one of the first consulting firms in the US focusing on the transfer of western management and financial know-how into transitional economies. The company was also involved in advising American corporations on entry strategies into the emerging markets of Europe and Asia. Dr. Olszewski has successfully led the efforts to form Joint Ventures in Poland, China and France. She was a President and CEO of G.O. International, Inc., that she cofounded with Dr. James P. Gilligan, a consulting firm specializing in business strategies for pharmaceutical industry and global technology transfer. G.O. International, Inc. merged with Herborium, Inc. in June 2002.


Prior to starting Herborium, Dr. Olszewski was Director of The Institute for International Business and Director of the MSIB Program at SetonHallUniversity where she is presently a Professor of Marketing and International Business. Dr. Olszewski is the author of over 100 publications and presentations in the US and abroad. She is a Member of The Women's Presidents Organization, an Executive Member of the American Marketing Association, Member of the Academy of International Business, AmericanAcademy of Management, and the International Platform Association. Dr. Olszewski is a recipient of the Valley Forge Foundation National Economic Excellence Award and a recipient of the International Business Award of the State of New Jersey.


http://www.shu.edu/academics/profile...(Department+of)


http://www.hoovers.com/company/Herbo.../sssxhi-1.html



James P. Gilligan, Ph.D. MSIB; Co- Founder, Chief Operating Officer
Dr. James Gilligan, a co-founder of Herborium, has over 25 years experience in the pharmaceutical and biotechnology industry, and over 10 years of business experience in China. Dr. Gilligan received his Ph.D. in Pharmacology and Toxicology from the University of Connecticut, during which time he completed a special research fellowship at the Cleveland Clinic Atherosclerosis Research Unit.


He performed his post-doctoral training at the Roche Institute of Molecular Biology. Dr. Gilligan is author or co-author of 15 US patents as well as multiple PCT patents and the author of numerous scientific publications. He also received a MS in International Business from SetonHallUniversity.


Dr. Gilligan is Vice President of Product Development at Unigene Laboratories Inc. Fairfield, NJ, a biopharmaceutical company. He was a founding member of Unigene in 1981 and participated in the design of its R&D facility in 1983 and the cGMP biotechnology manufacturing facility in 1993. His responsibilities have included coordination of all US and international pre-clinical research, toxicology, and regulatory filings as well as design and management of clinical studies. He was an integral part of the team that successfully registered the first "generic" biotechnology product in the EU via a centralized submission. Dr. Gilligan was responsible for coordinating with Warner Lambert (Pfizer) the oral salmon calcitonin program for the treatment and prevention of osteoporosis.


He was also responsible for the US program to register and license Fortical® Nasal Spray, obtain the Company's first FDA approval, as well as identifying new applications for Unigene's technology and negotiations with prospective partners.


http://people.forbes.com/profile/james-p-gilligan/40389


http://opa.yale.edu/news/article.aspx?id=7172



Dr. Aihua Qi Vice President, Traditional Chinese Medicine
Dr. Aihua Qi was among the first generation of China' medical experts following the founding of the People's Republic of China, who received eight years of interdisciplinary training in both Western medicine and Traditional Chinese Medicine (TCM). Dr. Qi's professional experience covers the full spectrum of healthcare including: teaching, research and practice in various renowned academic institutions, hospitals and clinics in the capacity of professor, pharmacist, researcher, and physician. She served in leadership positions in a number of projects focusing on: hepatitis, diabetes, anti-frostbite and cardiovascular diseases at leading Government and MilitaryHospitals.


Dr. Qi combined her medical training with an entrepreneurship in the late 1980s when she established and operated private medical clinics in the United States and Hong Kong. Over a period of twenty years in addition to private practice she also developed a number of safe and effective drugs based on unique herbal formulations, representing the innovative combination of western methodology and traditional Chinese medicinal theories. In particular she developed novel herbal medicines that improved liver function in patients with chronic hepatic disease.


Dr. Qi has also developed a formula that targeted dermatological problems related to acne and Rosacea; this product was recognized by the Chinese Ministry of Health as a drug and was granted an NDA. Her outstanding contributions to the field of medicine brought her scientific recognitions as the honorary president of Liaoning Traditional Chinese Medicine Institute, adjunct professor at the 302 Hospital of the Chinese People's Liberation Army, editor to the Chinese Journal of Infectious Diseases, and Council Member to the Liaoning Traditional Chinese Medicine Society, among others.


Dr. Qi is a graduate of Anshan Medical University where she completed her degree in Western Medicine (1967) and a graduate of Liaoning Traditional Chinese Medical Academic Institute where she specialized in Chinese Medicine.


http://www.admissions.cn/jzmu/


Dr. Liu Baocheng MBA/MSIB, Director Asian Office Herborium, PRC
Mr. Liu earned a B.A in economics and a Post-Graduate diploma in International Business Law from University of International Business and Economics (UIBE) in Beijing and an MBA and MSIB from Seton Hall University School of Business. He is fluent in English, Chinese and intermediate in Japanese. Mr. Liu currently runs the HERBORIUM, Inc. office in Beijing. Mr. Liu has served as the General Manager of a Sino/US JV introducing novel biotechnology products into the Chinese market. He was employed as the Chief Representative for Cathay Trading Inc. UK and HK overseeing all business development in Mainland China.
Mr. Liu also was the General Manager of Union Merchant Overseas, Ltd. UK where he was responsible for sourcing agricultural and chemical products from China and other Asian countries for EU markets. He has extensive experience with MOFTEC and International Trade procedures. Mr. Liu has consulted for AMOCO, and Hoescht Celenese to establish Joint Ventures in China. He has provided cross-cultural training courses for among others, Master Card, BASF,OTIS, and Citibank.


http://www.cibe.org.cn/en/page/Default.asp?ID=155


http://www.ceibs.edu/today/events/28585.shtml